Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...
Hosted on MSN2h
Galderma enters fierce European atopic dermatitis market with Nemluvio approval
Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...
Monthly Prescribing Reference4d
Rezpegaldesleukin Fast Tracked for Moderate to Severe Atopic Dermatitis
Rezpegaldesleukin is currently being investigated in the phase 2b REZOLVE-AD study (ClinicalTrials.gov Identifier: NCT06136741) in 398 adult patients with moderate to severe atopic dermatitis who ...
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric ...
Pharmabiz3d
US FDA grants fast track designation to Nektar Therapeutics’ rezpegaldesleukin to treat moderate-to-severe atopic dermatitis
US FDA grants fast track designation to Nektar Therapeutics’ rezpegaldesleukin to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 11, 2025, 16:00 Hrs ...
Managed Healthcare Executive10d
Tapinarof Cream Improves Symptoms and Quality of Life in Children with Severe Atopic Dermatitis
Tapinarof, however, offers a potential solution by improving the skin barrier, reducing inflammation and relieving itch ...
Medscape11d
Early Childhood Stress Linked to Increased Atopic Dermatitis Activity
Experiencing stressful life events in childhood was associated with an increased risk for active and severe atopic dermatitis ...
AI-enabled wearable sensor uses vibration to curb nocturnal scratching
Northwestern University researchers have tested a method to reduce the dreaded nocturnal itch-scratch cycle. Using an ...
FiercePharma4d
Incyte's JAK cream Opzelura picks up steam as company works to revive Jakafi XR dreams
Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...
Galderma's Nemluvio® (Nemolizumab) Approved In The European Union For Moderate-To-Severe Atopic Dermatitis And Prurigo N...
Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...